6d
Zacks Investment Research on MSNNevro Q4 Earnings & Revenues Beat Estimates, Gross Margin DownNevro Corp. NVRO reported a loss per share of 64 cents in the fourth quarter of 2024, wider than the year-ago quarter’s loss ...
Nevro Corp. (NYSE:NVRO – Get Free Report) has earned a consensus rating of “Reduce” from the thirteen research firms that are ...
Analysts at StockNews.com initiated coverage on shares of Nevro (NYSE:NVRO – Get Free Report) in a research note issued on ...
As previously announced on February 6, given the pending acquisition of Nevro (NVRO) by Globus Medical, Nevro is not issuing FY25 guidance, nor ...
Nevro Corp (NYSE:NVRO) is set to release its Q4 2024 earnings on Mar 4, 2025. The consensus estimate for Q4 2024 revenue is ...
Reports Q4 revenue $105.5M, consensus $102.61M. Cash, cash equivalents and short-term investments totaled $292.5M as of December 31, 2024, an ...
7d
Zacks.com on MSNNevro (NVRO) Reports Q4 Loss, Tops Revenue EstimatesNevro (NVRO) delivered earnings and revenue surprises of 18.99% and 1.49%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...
REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Nevro Corp. (NVRO) on Tuesday reported a loss of $53.1 million in its fourth quarter. On a per-share basis, the Redwood City ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results